Signaling pathways
-
BA4606 FuzapladibSummary: Fuzapladib (IS-741) is an orally active inhibitor of leukocyte function-related antigen type 1 activation, a leukocyte adhesion molecule. -
BA4609 AficamtenSummary: Aficamten (CK-274) is a novel cardiac myosin inhibitor. -
BA4610 DanicamtivSummary: Danicamtiv (MYK-491), an inotropic agent, is a selective denatured activator of cardiac actin.
-
BA4611 para-NitroblebbistatinSummary: para-Nitroblebbistatin is a non-cytotoxic, photostable, non-fluorescent, specific inhibitor of myosin II.
-
BA4612 PentachloropseudilinSummary: Pentachloropseudilin (AntibioticA15104Y; PCLP) is a reversible, variably potent myosin inhibitor.
-
BA4613 ATM-3507Summary: ATM-3507 is a potent inhibitor.
-
BA4614 MPH-220Summary: MPH-220 is a selective, orally active skeletal muscle inhibitor.
-
BA4615 SevasemtenSummary: Sevasemten is a variant inhibitor of skeletal muscle myosin.
-
BA4616 JB062Summary: JB062 is a non-muscle myosin inhibitor.
-
BA4617 JB002Summary: JB002 is a myosin II inhibitor.